Document Classification

Section Type: METHODS

Text: Eligible patients were randomized to receive one of the two treatment arms : Arm A-DP (docetaxel 75mg/m (2) D1, cisplatin 75mg/m (2) D1 repeated every 3weeks) until progression or unacceptable toxicity as the first-line treatment which was followed by FOLFIRI (irinotecan 150mg/m (2) D1, leucovorin 100mg/m (2) D1, 5-fluorouracil 3, 000 mg/m (2) D1-2 for 48h every 2weeks) upon disease progression as second-line chemotherapy ; Arm B-FOLFIRI as the first-line treatment until disease progression or unacceptable toxicity then followed by DP as the second-line treatment upon documented disease progression.